Top Markets
Coin of the day
Novartis AG Novartis AG

Novartis AG

NOVN
Rank in Stocks #51
Novartis AG researches, develops, manufactures, distributes, markets, and sells... Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still’s disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Share Price
$168.94
Market Cap
$321.11B
Change (1 day)
-1.08%
Change (1 year)
30.99%
Country
CH
Trade Novartis AG (NOVN)

Category

Price of NOVN with the market cap of B
Novartis AG Novartis AG
NOVN
$168.94
Market Capitalization of Novartis AG(NOVN)
Market Cap: $321.11B
As of September 2026 Novartis AG has a market cap of $321.11B. This makes Novartis AG the world's 51st most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.
Market cap history of Novartis AG from 1995 to 2026
NOVN compared with Top 5 Most Popular stocks
Price of NOVN Asset B Mkt. of B Results
Novartis AG Novartis AG
$2,931.55 $321.11B
$5.572T +1,635.23%
Novartis AG Novartis AG
$2,478.91 $321.11B
$4.712T +1,367.31%
Novartis AG Novartis AG
$2,143.51 $321.11B
$4.074T +1,168.78%
Novartis AG Novartis AG
$1,951.78 $321.11B
$3.710T +1,055.29%
Novartis AG Novartis AG
$1,463.06 $321.11B
$2.781T +766.01%